Michael Countryman, Raffi Barsoumian, Daniel Radcliffe and Reg Rogers in Privacy (photo by Joan Marcus)

Last week, The New York Times reported on a dispute between Theatre for a New Audience, one of the city’s major producers of classical theatre, and the acclaimed director Sam Gold. Gold had withdrawn from directing the company’s planned production of Hamlet, which was to star Oscar Isaac, the stage veteran and rising movie star. Gold cited artistic differences with TFANA’s leadership as the cause for the break, and the company’s artistic director was uncharacteristically public with his dismay. According to the article, Gold was shopping the production to other theatres, notably the Public Theater, and it appeared that he would be taking Isaac with him.

With only one side giving their account of the conflict, it’s impossible to parse what happened when, and who said what to whom. My attention, instead, drifted to the last paragraph of the article, which read: “Theatre for a New Audience ended up quickly making arrangements for a Measure for Measure production, directed by Simon Godwin, for next June. Without a star like Isaac, the theatre projected, Measure would make half the money that Hamlet would have.”

While Hamlet tends to be more popular than Measure in general, the implication of the article’s closing sentence, reflecting the sentiments of TFANA, is that the real loss is that of the ‘name’ performer, which will have an impact on the bottom line. That may well be true, though if it’s important to their planning, certainly the company has choice roles in Measure to offer up to other capable stars. I think Jessica Chastain would be a terrific Isabella, for example.

But should Off-Broadway companies be predicating their health on their ability to attract stars? Aren’t stars the essential ingredient of Broadway, with vastly more seats to fill and at a higher price?

That’s not to say that the idea of stars Off-Broadway is a new concept. I think back to the late Jessica Tandy at the Public in the early 1980s in Louise Page’s Salonika as an example of a legendary actor taking a role in a venue much smaller than the Broadway houses to which she was accustomed. But have we reached a point where the major Off-Broadway companies, subsidised theatres all, need names who have established themselves not just in the theatre, but in television or film as well?

Earlier this year at the Public, we saw Claire Danes, John Krasinski and Hank Azaria in Sarah Burgess’ Dry Powder, and right now Daniel Radcliffe is there in James Graham’s Privacy. This fall will see Rachel Weisz in David Hare’s Plenty. New York Theatre Workshop will have Daniel Craig and David Oyelowo in Othello (also directed by Sam Gold). George Takei will be at Classic Stage in John Doyle’s revival of Pacific Overtures. Matthew Broderick was at the Irish Repertory Theatre in Conor McPherson’s Shining City until just a couple of weeks ago. And so on.

None of this is invoked to question the talents of the actors involved, who absolutely should have the opportunity to do work on stages other than Broadway, even after they’ve achieved a level of fame that might well sustain a commercial run on the Great White Way. It’s also a credit to these companies that stars will forego the income and amenities of film, TV and Broadway to consider working there. The phenomenon is not new, though anecdotally it seems more prevalent than ever before.

But with more TV and film stars seemingly taking leading roles Off-Broadway as well as on, especially when it comes to plays, is the opportunity for solid working actors to be discovered in smaller houses being incrementally lost? After all, this year’s Tony winner for best featured actor in a play, Reed Birney, has only been in Broadway shows four times in his career, and there was a gap of more than 30 years between his first and second opportunity. It was Off-Broadway (and Off-Off-Broadway) that sustained him, but if more stars take leading roles, how will fine actors such as Birney manage to maintain their careers?

There’s no question that it is a special thrill to see a star who is also a superb actor in a small venue. But it is also a thrill to see great actors who may not yet have been ‘discovered’ and to watch younger actors hone their craft in major roles, as was the case with Nina Arianda in Venus in Fur. If the need for stars, that some bemoan is now a driving, even essential, force on Broadway, has trickled down to Off-Broadway as well, theatre may be denying itself the opportunity to create its own stars and falling prey to the drive toward ‘celebrity first’ that has permeated our culture. Indeed, this is reinforced by media outlets that only give coverage to theatre when there are big names on the stage; good work is no longer enough to merit mainstream media attention in many cases.

Off-Broadway seemed a place where theatre was holding out against this, but perhaps it has already lost its standing as a place where talent alone rules, with economic pressures increasingly underlying some creative choices. The question is whether it’s too late to do anything about it, or whether anyone actually wants to.

“I have a guy.”

I used to hear this phrase a lot, from various people not in the theatre industry, who always seemed to be able to acquire tickets to sold-out Broadway shows with ease. I don’t hear it so much anymore, because now everybody has a guy, whether ‘he’ goes by the name of StubHub or Ticketmaster Fan-to-Fan resale or something along those lines.

In 2007, when New York State lifted caps on the amount that ticket resellers could charge over face value, long-standing opposition from the commercial theatre community had gone silent. Only six years after The Producers had introduced ‘VIP’ or ‘premium’ pricing, using the argument that these higher priced tickets would make it possible for productions and artists to realise more income via direct sales, most shows followed suit, with their sales success directly correlated to audience demand. Resellers jumped into the fray, more openly than ever before. But now, with the rise of automated bots that gobble up tickets for sale online, it seems to be getting even harder for the average ticket buyer to acquire seats at something close to a reasonable price, even from the official ticket outlet, in the already expensive Broadway arena, if they can get them at all.

In “Why Can’t New Yorkers Get Tickets?,” a report issued last week by the state attorney general, the results of which surprised no one familiar with what’s been generally evident for some time, it was affirmed that a combination of preferred sales that limited the number of seats actually made available to the public, along with mass acquisition of tickets by bots, were biting into ticket inventory in a big way. While there are laws in New York against the use of bots by resellers, and a few fines have been levied, it’s going to take a lot more scrutiny to police such sales. As it seems in so many aspects of modern life, the people determined to get a leg up on everyone else, even when their actions are criminal, seem to be further ahead of the technology curve than those chasing them.

Theatre is not alone in this struggle; the same holds true for rock concerts and sporting events. But any given theatre is so much smaller than those venues that the problem seems more pronounced, as does the heightened demand that drives prices up, a situation most apparent today with Hamilton, which is enjoying demand that’s comparable to those experienced, in my theatregoing life, by, among others, Cats, Phantom, Les Miserables, Miss Saigon, the 1992 Guys and Dolls revival, Rent, Jersey Boys and The Book of Mormon.

So this isn’t a new story, even if it has been turbocharged by technology and made more apparent by the rise of online sales. It’s based in the fundamentals of supply and demand. Some theatre buffs might feel some small sense of pride that theatre is able to generate this kind of interest and desire. But in the process, it only emphasises how expensive theatregoing can be, even when only a few shows command eye-popping prices on the open market.

Broadway is a predominantly commercial enterprise, so it’s unlikely that capitalistic efforts will ever return ticket sales to something close to accessible for the majority; the real battle is over who gets their hands on the most significant part of the revenues being generated. However, just as dynamic pricing spread from the commercial realm to subsidised companies, one can’t help but wonder what’s happening when celebrities appear in regional houses, or when 200-seat theatres such as New York Theatre Workshop start selling tickets to Othello with David Oyelowo and Daniel Craig in the leads this fall. While NYTW made an effort to limit resales during its run of Lazarus by requiring photo ID to pick up seats, that will only go so far.

As someone who was extremely surprised when the commercial theatre industry ended its opposition to resale caps almost a decade ago, I certainly applaud efforts to put all ticket buyers on a level playing field and stem the tide of unbridled price hikes, both official and illicit. At a time when income inequality continues to divide America in so many things, it’s a worthy effort, though I fear a losing battle which has probably already had an insidious and deleterious effect on the perception of theatregoing as an entertainment option for all, even beyond the confines of Manhattan.

Somehow, some way, people with the means to do so will manage to get the tickets they want, when they want. They will always have a guy, even if their guy is now a silicon chip.

This essay originally appeared in The Stage.

Macbeth. Twelfth Night. Richard III. Romeo and Juliet. No Man’s Land. Waiting For Godot. Betrayal. The Winslow Boy.

The syllabus for a university survey course in drama? No. Instead, it’s the roster of eight of the 16 titles scheduled to open on Broadway between now and the end of 2013.

To be sure, British plays, artists and productions haven’t ever been strangers to Broadway, but this preponderance of works – featuring actors such as Jude Law, Mark Rylance, Rachel Weisz, Daniel Craig, Anne-Marie Duff, Stephen Fry, Orlando Bloom, Roger Rees, Ian McKellen and Patrick Stewart – in the 40 theatres that comprise Broadway, all at the same time, is an embarrassment of riches. Add in concurrent Off-Broadway productions of A Midsummer Night’s Dream with David Harewood and Kathryn Hunter (opening the new Theatre for a New Audience space in Brooklyn) and Michael Gambon and Eileen Atkins in All That Fall, and it appears that Anglophilia is running rampant in the playhouses of New York.

Much of this is coincidence, since it’s not as if producers conspire on themes. Indeed, from a marketing standpoint, it’s not necessarily even a good idea, since the theatregoers most drawn to this work may have to face some tough buying decisions unless they have unlimited resources and time. Cultural tourists won’t even be able to fit all of these terrific sounding shows in, should they fly to the city for merely a long weekend.

But whether the productions are transfers from the UK or newly minted in America, as is the case with No Man’s Land, Romeo and Juliet, and Betrayal, the British imprimatur seems as if it’s a requirement this year, even if only in part. UK director David Leveaux is staging Romeo and Juliet with a North American cast capped by Bloom. US director Julie Taymor tapped Harewood and Hunter for A Midsummer Night’s Dream, her first project since the highly-publicised and contentious Spiderman: Turn Off The Dark (a tell-all book by her collaborator Glen Berger will be released just as Midsummer performances begin). Even the US classic The Glass Menagerie is being helmed by John Doyle. Only Classic Stage Company’s Romeo and Juliet, with Elizabeth Olsen and TR Knight, is wholly comprised of American artists, though their Romeo is Japan-born.

The English theatre can certainly take pride in this abundance of talent exported to American shores, and I look forward to each and every one of these shows enthusiastically. Indeed, I’ll pass on my annual autumn trip to London since I’ll need only take the subway and not British Airways.

But it does beg the question of whether classical work can succeed on Broadway without a UK connection. Are producers giving up on our best American actors and directors taking on British and Irish pieces without at least some of that heritage in the shows’ DNA? To be sure, not-for-profit companies may lean American overall (LCT’s Macbeth is Ethan Hawke), but has public television conditioned us to desire the “genuine” article? Great American plays appear on British stages frequently, ranging from A View From The Bridge to Fences to Clybourne Park, without the perpetual need to import Americans, let alone the cream of American talent, to make them work. Yet the power of UK casting appears to be such that even multiple Macbeths are deemed economically viable, with Alan Cumming having played virtually all of the roles on Broadway only months ago and Kenneth Branagh due at the Park Avenue Armory in June 2014.

I don’t like calling attention to national divisions when it comes to art, but the fall theatre season in New York simply can’t be overlooked. Despite the luxury of all of the great theatre on tap, the timing sends the message to US actors, theatre students, critics and audiences that when it comes to staging foreign classics, the talent exchange flows more strongly from west to east than in the other direction.

But looking on the bright side, perhaps this means we’ll soon enjoy one more benefit of the English stage, and be able to buy ice cream at the interval.